OverviewSuggest Edit

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

TypePublic
Founded2009
HQNorwood, MA, US
Websitecorbuspharma.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)141(+84%)
Job Openings7
Revenue (FY, 2020)$3.9 M(-89%)
Share Price (Jul 2021)$1.5(-3%)
Cybersecurity ratingAMore

Key People/Management at Corbus Pharmaceuticals

Yuval Cohen

Yuval Cohen

Chief Executive Officer, Director
Alan Holmer

Alan Holmer

Chairman of the Board
Avery W. Catlin

Avery W. Catlin

Director
Craig Millian

Craig Millian

Chief Commercial Officer
Barbara White

Barbara White

Chief Medical Officer and Head of Research
Sean Moran

Sean Moran

Chief Financial Officer
Show more

Corbus Pharmaceuticals Office Locations

Corbus Pharmaceuticals has an office in Norwood
Norwood, MA, US (HQ)
500 River Ridge Dr
Show all (1)

Corbus Pharmaceuticals Financials and Metrics

Corbus Pharmaceuticals Revenue

Corbus Pharmaceuticals's revenue was reported to be $3.94 m in FY, 2020
USD

Revenue (Q1, 2021)

647.8k

Net income (Q1, 2021)

(16.1m)

EBIT (Q1, 2021)

(15.4m)

Market capitalization (15-Jul-2021)

190.1m

Closing stock price (15-Jul-2021)

1.5

Cash (31-Mar-2021)

66.6m

EV

149.9m
Corbus Pharmaceuticals's current market capitalization is $190.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

648.4k1.9m2.4m4.8m36.1m3.9m

General and administrative expense

1.4m3.6m6.5m9.0m13.0m23.6m28.5m

R&D expense

1.3m5.9m15.4m26.0m48.6m89.6m98.3m

Operating expense total

2.6m9.5m21.9m35.0m61.6m113.2m126.7m
Quarterly
USDQ3, 2014

Financial Leverage

1.1 x
Show all financial metrics

Corbus Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Corbus Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Corbus Pharmaceuticals Online and Social Media Presence

Embed Graph

Corbus Pharmaceuticals Company Culture

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Corbus Pharmaceuticals News and Updates

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the Phase …

Thinking about buying stock in AMC, Corbus Pharmaceuticals, Syros Pharmaceuticals, Canaan, or Lineage Cell Therapeutics?

NEW YORK, June 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, CRBP, SYRS, CAN, and LCTX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Norwood, MA, June 01, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced licensing deals for two new monoclonal antibodies (mAbs), CRB-601 and CRB-602, that target integrins to inhibit activation of transforming growth factor …

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress

Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at …

Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Execu…

Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Norwood, MA, March 30, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last subject completed th…
Show more

Corbus Pharmaceuticals Blogs

Corbus Pharmaceuticals Announces Adjournment of Annual Meeting

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned its 2021 Annual …

Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates

Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022 Corbus is actively engaging with potential partners to expand its pipeline through acquisition of exter…

Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)

First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE) Cooperative Network Topline data expected in the second half of …

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results

  ● Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021   ● Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with clinical studies projected for 2022   ● Corbus is actively engaging with potential partne…

Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicin…

Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (…
Show more

Corbus Pharmaceuticals Frequently Asked Questions

  • When was Corbus Pharmaceuticals founded?

    Corbus Pharmaceuticals was founded in 2009.

  • Who are Corbus Pharmaceuticals key executives?

    Corbus Pharmaceuticals's key executives are Yuval Cohen, Alan Holmer and Avery W. Catlin.

  • How many employees does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 141 employees.

  • What is Corbus Pharmaceuticals revenue?

    Latest Corbus Pharmaceuticals annual revenue is $3.9 m.

  • What is Corbus Pharmaceuticals revenue per employee?

    Latest Corbus Pharmaceuticals revenue per employee is $27.9 k.

  • Who are Corbus Pharmaceuticals competitors?

    Competitors of Corbus Pharmaceuticals include Venus Pharma, MindMed and Dalton Pharma Services.

  • Where is Corbus Pharmaceuticals headquarters?

    Corbus Pharmaceuticals headquarters is located at 500 River Ridge Dr, Norwood.

  • Where are Corbus Pharmaceuticals offices?

    Corbus Pharmaceuticals has an office in Norwood.

  • How many offices does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 1 office.